PE20000550A1 - Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv - Google Patents
Composicion de un derivado de bencimidazol util como anti-viral y anti-hivInfo
- Publication number
- PE20000550A1 PE20000550A1 PE1999000422A PE00042299A PE20000550A1 PE 20000550 A1 PE20000550 A1 PE 20000550A1 PE 1999000422 A PE1999000422 A PE 1999000422A PE 00042299 A PE00042299 A PE 00042299A PE 20000550 A1 PE20000550 A1 PE 20000550A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- hiv
- benzimidazole derivative
- viral
- derivative useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DE 250 mg A 6000 mg DE UN DERIVADO DE BENCIMIDAZOL DE FORMULA I, DONDE X ES H, HALOGENO, ALQUILO C1-C7, ALCOXI C1-C7; n ES 0-4; Y ES H, CLORO, NITRO, OXICLORO, METILO, ETILO; R ES H, ALQUILO C1-C8; R2 ES 4-TIAZOLILO, TAL COMO 2-(4-TIAZOLIL)BENCIMIDAZOL (TIABENDAZOL). TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN INHIBIDOR DE PROTEASA, AZIDOVUDINA (AZT), EPIVIR (3TC), DIDEOXICITOSINA (ddC), DIDEOXINOSINA (ddI). LA COMPOSICION PUEDE SER UTIL PARA PREVENIR EL DESARROLLO DE CEPAS DE VIRUS RESISTENTES AL VIH, SUPRIMIR EL VIH, INFLUENZA, RINOVIRUS, HEPATITIS, MICROVIRUS (HERPES O INFLUENZA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8138498A | 1998-05-19 | 1998-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20000550A1 true PE20000550A1 (es) | 2000-06-29 |
Family
ID=22163807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1999000422A PE20000550A1 (es) | 1998-05-19 | 1999-05-19 | Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv |
Country Status (19)
Country | Link |
---|---|
US (1) | US6245789B1 (es) |
EP (1) | EP1079831A1 (es) |
JP (1) | JP2002515432A (es) |
KR (1) | KR20010043709A (es) |
CN (1) | CN1301158A (es) |
AR (1) | AR019305A1 (es) |
AU (1) | AU4004299A (es) |
BR (1) | BR9911043A (es) |
CA (1) | CA2329877A1 (es) |
CO (1) | CO5050303A1 (es) |
HU (1) | HUP0103319A2 (es) |
ID (1) | ID27457A (es) |
IL (1) | IL139002A0 (es) |
NO (1) | NO20005839L (es) |
PE (1) | PE20000550A1 (es) |
PL (1) | PL344223A1 (es) |
SK (1) | SK17442000A3 (es) |
TR (1) | TR200003383T2 (es) |
WO (1) | WO1999059585A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
US6423734B1 (en) * | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
US6242461B1 (en) * | 2000-01-25 | 2001-06-05 | Pfizer Inc. | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
US6462062B1 (en) * | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6608096B1 (en) * | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
WO2002041891A2 (en) * | 2000-11-01 | 2002-05-30 | The Procter & Gamble Company | Hiv treatment with benzimidazoles |
US6919352B2 (en) | 2000-12-15 | 2005-07-19 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
DE60112330T2 (de) | 2000-12-15 | 2006-04-13 | Glaxo Group Ltd., Greenford | Pyrazolopyridinderivate |
ATE274515T1 (de) | 2001-03-08 | 2004-09-15 | Smithkline Beecham Corp | Pyrazolopyridinderivate |
EP1372643A1 (en) | 2001-03-30 | 2004-01-02 | Smithkline Beecham Corporation | Pyrazolopyridines, process for their preparation and use as therapeutic compounds |
DE60212949T2 (de) | 2001-04-10 | 2007-01-04 | Smithkline Beecham Corp. | Antivirale pyrazolopyridin verbindungen |
ATE296826T1 (de) | 2001-04-27 | 2005-06-15 | Smithkline Beecham Corp | Pyrazolo(1,5)pyridinderivate |
PL366827A1 (en) * | 2001-06-21 | 2005-02-07 | Smithkline Beecham Corporation | Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
WO2003031446A1 (en) | 2001-10-05 | 2003-04-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
WO2003050120A1 (en) * | 2001-12-11 | 2003-06-19 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
JP2005521712A (ja) * | 2002-03-26 | 2005-07-21 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | 弱塩基の可溶化 |
WO2004033454A1 (en) | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
AU2003900064A0 (en) * | 2003-01-09 | 2003-01-23 | Penam Investments Pty. Ltd. | A method of treatment or prophylaxis of viral infection. |
JP2005060362A (ja) * | 2003-07-28 | 2005-03-10 | Shionogi & Co Ltd | セスキテルペン誘導体を含有する抗HIV剤、抗BVDV剤、抗HCV剤又は抗CoV剤 |
EP2251010A1 (en) | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
US9655962B2 (en) * | 2013-03-15 | 2017-05-23 | Camas Incorporated | Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities |
FR3057865A1 (fr) * | 2016-10-21 | 2018-04-27 | Laboratoire Michel Iderne | Composition chimique |
TW201936193A (zh) * | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 使用組合產品治療rsv |
KR102342313B1 (ko) * | 2021-08-27 | 2021-12-24 | (주)바이오메트릭스 테크놀로지 | 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3010968A (en) | 1959-11-25 | 1961-11-28 | Du Pont | Process for manufacture of certain alkyl esters of benzimidazole carbamic acids |
NL134354C (es) | 1963-05-23 | |||
US3499761A (en) | 1964-07-20 | 1970-03-10 | Gaf Corp | Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents |
US3541213A (en) | 1966-05-06 | 1970-11-17 | Du Pont | Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles |
US3881014A (en) | 1968-11-05 | 1975-04-29 | Bayer Ag | N-tritylimidazoles for treating fungal infections |
BE759337A (fr) | 1969-11-24 | 1971-05-24 | Lilly Co Eli | Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones |
US3956262A (en) | 1970-12-09 | 1976-05-11 | Beecham Group Limited | Triazenoimidazoles |
US3738995A (en) | 1971-05-14 | 1973-06-12 | Du Pont | Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates |
FR2155888A1 (en) | 1971-10-13 | 1973-05-25 | Agot Aime | Solid anthelmintic composn - for more economical treatment of ruminants |
US4046906A (en) | 1973-04-21 | 1977-09-06 | Hoechst Aktiengesellschaft | Salts of alkyl 2-benzimidazole-carbamate |
HU193951B (en) | 1985-03-11 | 1987-12-28 | Richter Gedeon Vegyeszet | Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them |
US4731366A (en) | 1986-08-05 | 1988-03-15 | Harbor Branch Oceanographic Institution, Inc. | Discorhabdin compositions and their methods of use |
GB2210875B (en) | 1987-10-09 | 1991-05-29 | Farmos Oy | Aromatase inhibiting 4(5)-imidazoles |
US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
US5114951A (en) | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
US5149527A (en) | 1990-09-18 | 1992-09-22 | Oncotech, Inc. | Immunopotentiating protocol for chemotherapy-responsive tumors |
US5310748A (en) | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
US5364875A (en) | 1992-05-11 | 1994-11-15 | The Du Pont Merck Pharmaceutical Company | Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis |
US5290801A (en) | 1992-05-29 | 1994-03-01 | The Du Pont Merck Pharmaceutical Company | Benzimidazoles for the treatment of atherosclerosis |
CA2140653A1 (en) | 1992-08-12 | 1994-03-03 | Irene Abraham | Protein kinase inhibitors and related compounds combined with taxol |
KR100311551B1 (ko) | 1993-03-31 | 2001-12-28 | 폴락 돈나 엘. | Aids 치료용 약제학적 배합물 중의 hiv 프로테아제 억제제 |
US5434163A (en) | 1993-05-14 | 1995-07-18 | The Medical College Of Pennsylvania | Treatment of Cryptococcus neoformans infection |
JP3213471B2 (ja) | 1994-04-13 | 2001-10-02 | ポーラ化成工業株式会社 | 薬効成分含有リポソーム製剤の製造方法 |
ZA962880B (en) | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
US5656615A (en) | 1995-04-12 | 1997-08-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals |
US5665713A (en) | 1995-04-12 | 1997-09-09 | Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
ATE367808T1 (de) | 1995-04-12 | 2007-08-15 | Uaf Technologies And Res Llc | N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren |
ZA962879B (en) | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
US5629341A (en) | 1995-04-12 | 1997-05-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
NZ305784A (en) | 1995-04-12 | 2001-03-30 | Procter & Gamble | Benzimidazole containing medicaments for treating cancers, tumors and viral infections |
US6200992B1 (en) | 1995-06-07 | 2001-03-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
MX9707809A (es) | 1995-06-07 | 1998-01-31 | Procter & Gamble | Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres. |
HUP9802634A3 (en) | 1995-06-07 | 1999-05-28 | Procter & Gamble | Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia |
US5665751A (en) | 1995-06-07 | 1997-09-09 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
SK14298A3 (en) | 1995-08-03 | 1998-09-09 | Procter & Gamble | Use of griseofulvin for inhibiting the growth of cancers |
CZ33798A3 (cs) | 1995-08-04 | 1998-06-17 | The Procter & Gamble Company | Použití flukonazolu pro inhibování růstu rakovin |
US5908855A (en) | 1996-07-16 | 1999-06-01 | The Procter & Gamble Company | Compositions for treating viral infections |
US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
PE11499A1 (es) | 1997-05-16 | 1999-03-01 | Procter & Gamble | Tratamiento del hiv y cancer |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
-
1999
- 1999-05-17 US US09/312,949 patent/US6245789B1/en not_active Expired - Fee Related
- 1999-05-19 TR TR2000/03383T patent/TR200003383T2/xx unknown
- 1999-05-19 KR KR1020007012938A patent/KR20010043709A/ko not_active Application Discontinuation
- 1999-05-19 PE PE1999000422A patent/PE20000550A1/es not_active Application Discontinuation
- 1999-05-19 WO PCT/US1999/011059 patent/WO1999059585A1/en not_active Application Discontinuation
- 1999-05-19 SK SK1744-2000A patent/SK17442000A3/sk unknown
- 1999-05-19 JP JP2000549250A patent/JP2002515432A/ja not_active Withdrawn
- 1999-05-19 HU HU0103319A patent/HUP0103319A2/hu unknown
- 1999-05-19 IL IL13900299A patent/IL139002A0/xx unknown
- 1999-05-19 EP EP99923219A patent/EP1079831A1/en not_active Withdrawn
- 1999-05-19 CA CA002329877A patent/CA2329877A1/en not_active Abandoned
- 1999-05-19 AR ARP990102384A patent/AR019305A1/es unknown
- 1999-05-19 CO CO99030834A patent/CO5050303A1/es unknown
- 1999-05-19 ID IDW20002656A patent/ID27457A/id unknown
- 1999-05-19 PL PL99344223A patent/PL344223A1/xx unknown
- 1999-05-19 BR BR9911043-1A patent/BR9911043A/pt not_active IP Right Cessation
- 1999-05-19 CN CN99806363A patent/CN1301158A/zh active Pending
- 1999-05-19 AU AU40042/99A patent/AU4004299A/en not_active Abandoned
-
2000
- 2000-11-17 NO NO20005839A patent/NO20005839L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL344223A1 (en) | 2001-10-08 |
JP2002515432A (ja) | 2002-05-28 |
AU4004299A (en) | 1999-12-06 |
NO20005839L (no) | 2001-01-16 |
AR019305A1 (es) | 2002-02-13 |
US6245789B1 (en) | 2001-06-12 |
SK17442000A3 (sk) | 2001-08-06 |
CO5050303A1 (es) | 2001-06-27 |
IL139002A0 (en) | 2001-11-25 |
EP1079831A1 (en) | 2001-03-07 |
CA2329877A1 (en) | 1999-11-25 |
HUP0103319A2 (hu) | 2002-05-29 |
WO1999059585A1 (en) | 1999-11-25 |
BR9911043A (pt) | 2001-02-13 |
NO20005839D0 (no) | 2000-11-17 |
TR200003383T2 (tr) | 2001-03-21 |
ID27457A (id) | 2001-04-12 |
CN1301158A (zh) | 2001-06-27 |
KR20010043709A (ko) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20000550A1 (es) | Composicion de un derivado de bencimidazol util como anti-viral y anti-hiv | |
PE20100363A1 (es) | Composiciones que comprenden nucleosidos | |
BRPI0408396A (pt) | pelìculas de dissolução rápida, consumìveis por via oral, contendo agentes farmaceuticamente ativos | |
CY1107899T1 (el) | 6.αλφα., 9.αλφα. - διφθορο-17.αλφα.-(2-φουρανυλοανθρακοξυλικο) οξυ-11.βητα.-υδροξυ-16.αλφα.-μεθυλο-3-οξο-ανδροστα-1,4-διενιο-17-ανθρακοθειϊκο οξυ s-φθορομεθυλο εστερας ως αντιφλεγμονωδης παραγοντας | |
BR0116032A (pt) | imidazoquinolinas substituìdas com sulfonamido éster | |
EA200100541A1 (ru) | Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов | |
ECSP055869A (es) | Vacuna hpv-16 y -18 l1 vlp | |
AR067030A2 (es) | Composiciones farmaceuticas | |
RS51645B (en) | 4-FLUORO-N-INDAN-2-ILBENZAMIDE AND ITS USE AS PHARMACEUTICALS | |
DE502005010427D1 (de) | Physiologisch aktive zusammensetzung gegen diabetes | |
BR9811803A (pt) | Comprido multiparticular aperfeiçoado de dissolução rápida | |
AR098808A2 (es) | Una forma de dosificación farmacéutica de fusión instantánea que se desintegrará en la boca en un tiempo de 25 segundos | |
PE20130209A1 (es) | Derivados de uracilo o timina para tratar la hepatitis c | |
MA29550B1 (fr) | Derives de n- (pyridine-2-yl) - sulfonamide | |
MA27509A1 (fr) | Formulations a liberation prolongee contenant de la lamotrigine | |
PE20080093A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
PE20001036A1 (es) | Tabletas bioadhesivas para hidratacion progresiva y metodos para su elaboracion y uso | |
AR029825A1 (es) | Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma | |
ES2182255T3 (es) | Agente de blanqueo fluorescente. | |
PE20010071A1 (es) | Composicion de un inhibidor de pde5 | |
PE61699A1 (es) | Composicion farmaceutica de lamivudina | |
BR0309028A (pt) | Compostos policìclicos como antagonistas potentes de alfa2-adrenoceptores | |
ES2188766T3 (es) | Composicion farmaceutica que contiene lamotrigina. | |
AR018706A1 (es) | Uso de una composicion farmaceutica para tratamiento de infecciones virales | |
PE78899A1 (es) | Composicion de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |